Leishmaniasis in humans: drug or vaccine therapy?

M Ghorbani, R Farhoudi - Drug design, development and therapy, 2017 - Taylor & Francis
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …

Possibilities and challenges for developing a successful vaccine for leishmaniasis

S Srivastava, P Shankar, J Mishra, S Singh - Parasites & vectors, 2016 - Springer
Leishmaniasis is a vector-borne disease caused by different species of protozoan parasites
of the genus Leishmania. It is a major health problem yet neglected tropical diseases, with …

Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniases and viral …

C Bandi, JA Mendoza-Roldan, D Otranto, A Alvaro… - Parasites & …, 2023 - Springer
Parasites of the genus Leishmania are unusual unicellular microorganisms in that they are
characterized by the capability to subvert in their favor the immune response of mammalian …

Leishmania tarentolae and Leishmania infantum in humans, dogs and cats in the Pelagie archipelago, southern Italy

R Iatta, JA Mendoza-Roldan, MS Latrofa… - PLoS Neglected …, 2021 - journals.plos.org
Visceral leishmaniasis (VL) caused by Leishmania infantum is endemic in the
Mediterranean basin with most of the infected human patients remaining asymptomatic …

Leishmaniasis and various immunotherapeutic approaches

Y Taslimi, F Zahedifard, S Rafati - Parasitology, 2018 - cambridge.org
Leishmaniasis is a vector-borne infectious disease caused by multiple Leishmania (L.)
species with diverse clinical manifestations. There is currently no vaccine against any form …

Detection of Leishmania tarentolae in lizards, sand flies and dogs in southern Italy, where Leishmania infantum is endemic: hindrances and opportunities

JA Mendoza-Roldan, MS Latrofa, R Iatta… - Parasites & …, 2021 - Springer
Background Leishmania tarentolae is a protozoan isolated from geckoes (Tarentola
annularis, Tarentola mauritanica), which is considered non-pathogenic and is transmitted by …

Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil

S Regina-Silva, AMLT Feres, JC França-Silva, ES Dias… - Vaccine, 2016 - Elsevier
Background A canine vaccine remains a promising approach for effective control of visceral
leishmaniasis (VL), given its complex epidemiology in areas where zoonotic VL is prevalent …

[HTML][HTML] Development of Leishmania vaccines: predicting the future from past and present experience

JM Mutiso, JC Macharia, MN Kiio… - Journal of biomedical …, 2013 - ncbi.nlm.nih.gov
Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement
and fatal systemic infection. Resistance to infection is associated with a T-helper-1 immune …

Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives

AP Fernandes, EAF Coelho… - Current opinion in …, 2012 - Elsevier
Visceral leishmaniasis is a major health problem in Latina America, as well as the
Mediterranean region of Europe and Asia. We aimed to develop a vaccine against visceral …

Antigenicity and Protective Efficacy of a Leishmania Amastigote-specific Protein, Member of the Super-oxygenase Family, against Visceral Leishmaniasis

VT Martins, MA Chavez-Fumagalli… - PLoS neglected …, 2013 - journals.plos.org
Background The present study aimed to evaluate a hypothetical Leishmania amastigote-
specific protein (LiHyp1), previously identified by an immunoproteomic approach performed …